Stability and sterility of a recombinant factor VIII concentrate (Bioclate(TM)) prepared for continuous infusion prophylaxis

被引：0
|
作者：
Belgaumi, AF
Patrick, CC
Tonkel, S
Deitcher, SR
Jude, S
机构：
[1] CHILDRENS RES HOSP, MEMPHIS, TN USA
[2] UNIV TENNESSEE, MEMPHIS, TN USA
来源：
THROMBOSIS AND HAEMOSTASIS | 1997年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：P2092 / P2092
页数：1
相关论文
共 50 条
  • [21] Treatment of factor VIII inhibitors with continuous infusion of factor VIII.
    Rintels, P
    Costa, L
    BLOOD, 2000, 96 (11) : 88B - 88B
  • [22] vWF-FVIII stability of reconstituted high purity factor VIII concentrate (Alphanate(TM)).
    Eran, H
    Xu, H
    Dimmick, D
    Cakaroglu, H
    Motokubota, T
    Herring, S
    Bhattacharya, P
    BLOOD, 1995, 86 (10) : 3462 - 3462
  • [23] Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products
    Iorio, A.
    Krishnan, S.
    Myren, K. J.
    Lethagen, S.
    Mccormick, N.
    Yermakov, S.
    Karner, P.
    HAEMOPHILIA, 2017, 23 (03) : 408 - 416
  • [24] FDA Approves Recombinant Factor VIII Concentrate for Hemophilia A
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (04) : 269 - 269
  • [25] Potency measurements of recombinant factor IX concentrate (rFIX) and suitability for continuous infusion.
    Prondzinski, MV
    Barthels, M
    Aschermann, G
    Rutjes, J
    Ehrlich, H
    Ganser, A
    BLOOD, 1998, 92 (10) : 102B - 102B
  • [26] A STABILITY MONITORING AND EASTBLISHMENT FOR FACTOR VIII: CONCENTRATE
    Seo, J. S.
    Lee, N. R.
    Oho, H. J.
    Nam, J. S.
    Hong, S. H.
    Kang, S. Y.
    Ban, S. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 754 - 754
  • [27] THE PHARMACOKINETICS OF RECOMBINANT FACTOR-VIII (RECOMBINATE(R)) UNDER CONTINUOUS-INFUSION
    LEE, M
    KESSLER, C
    WHITE, GC
    GOMPERTS, ED
    COURTER, SG
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1015 - 1015
  • [28] Continuous infusion of porcine factor VIII: stability, microbiological safety and clinical experience
    DiMichele, DM
    Gorman, PO
    Kasper, CK
    Mannucci, PM
    Santagostino, E
    Hay, CRM
    HAEMOPHILIA, 2002, 8 : 9 - 12
  • [29] Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor VIII FC fusion protein and other recombinant factor VIII products
    Iorio, A.
    Krishnan, S.
    Myren, K-J
    Lethagen, S.
    McCormick, N.
    Karner, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 324 - 324
  • [30] Continuous infusion of recombinant porcine factor VIII for neurosurgical management of intracranial haemorrhage in a patient with severe haemophilia A with factor VIII inhibitor
    Ruan, Gordon J.
    Mao, Jimmy J.
    Sytsma, Terin T.
    Akogyeram, Ivy I.
    Wang, Yucai
    Ashrani, Aneel A.
    Pruthi, Rajiv K.
    HAEMOPHILIA, 2020, 26 (03) : E141 - E144
12345